

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Ralph M. ELLISON et al.

Title: *COMPOSITIONS AND METHODS FOR THE TREATMENT OF  
PRIMARY AND METASTATIC NEOPLASTIC DISEASES USING  
ARSENIC COMPOUNDS*

Prior Appl. No.: 09/173,531, filed 10/15/1998

Serial No.: Unassigned

Filing Date: 10/28/2003

**CONTINUING PATENT APPLICATION**  
**TRANSMITTAL LETTER**

Mail Stop PATENT APPLICATION  
Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Transmitted herewith for filing under 37 C.F.R. § 1.53(b) is a:

☐ Continuation    ☒ Division    ☐ Continuation-In-Part (CIP)

of the above-identified copending prior application in which no patenting, abandonment, or termination of proceedings has occurred. Priority to the above-identified prior application is hereby claimed under 35 U.S.C. § 120 for this continuing application. The entire disclosure of the above-identified prior application is considered as being part of the disclosure of the accompanying continuing application and is hereby incorporated by reference therein.

☒ Applicant claims small entity status under 37 CFR 1.27.

Enclosed are:

☒ Specification, Claim(s), and Abstract (40 pages).



☒ Informal drawings (4 sheets, Figures 1-4).

☒ Declaration and Power of Attorney (5 pages).

☐ Assignment of the invention to PolaRx Biopharmaceuticals, Inc..

☒ Small Entity statement.

☒ Preliminary Amendment.



☒ Application Data Sheet (37 CFR 1.76).

The filing fee is calculated below:

	Claims as Filed	Included in Basic Fee	Extra Claims	Rate	Fee Totals
Basic Fee				\$750.00	\$750.00
Total Claims:	11	- 20	= 0	x \$18.00	= \$0.00
Independents:	1	- 3	= 0	x \$84.00	= \$0.00
If any Multiple Dependent Claim(s) present:			+	\$280.00	= \$0.00
				SUBTOTAL:	= \$750.00
<input checked="" type="checkbox"/> Small Entity Fees Apply (subtract ½ of above):					= \$375.00
				TOTAL FILING FEE:	= \$375.00

- ☒ A check in the amount of \$375.00 to cover the filing fee is enclosed.
- ☐ The required filing fees are not enclosed but will be submitted in response to the Notice to File Missing Parts of Application.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date 28 August 2003

By

Stephen A. Bent

FOLEY & LARDNER  
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5404

Facsimile: (202) 672-5399

Stephen A. Bent  
Attorney for Applicant  
Registration No. 29,768

***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***

Applicant: Ralph M. ELLISON et al.

Title: *COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRIMARY  
AND METASTATIC NEOPLASTIC DISEASES USING ARSENIC  
COMPOUNDS*

Appl. No.: Unassigned

Filing Date: 10/28/2003

**ASSERTION OF SMALL ENTITY STATUS**

Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.27 (c)(1), Applicants hereby assert entitlement to small entity status in the above-identified application.

Respectfully submitted,

Date 28 August 2003

By S. A. Bent

FOLEY & LARDNER  
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5404

Facsimile: (202) 672-5399

Stephen A. Bent  
Attorney for Applicant  
Registration No. 29,768